The Extracellular Domain of CD83 Inhibits Dendritic Cell–mediated T Cell Stimulation and Binds to a Ligand on Dendritic Cells by Lechmann, Matthias et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/12/1813/09 $5.00
Volume 194, Number 12, December 17, 2001 1813–1821
http://www.jem.org/cgi/content/full/194/12/1813
 
1813
 
The Extracellular Domain of CD83 Inhibits
Dendritic Cell–mediated T Cell Stimulation and
Binds to a Ligand on Dendritic Cells
 
Matthias Lechmann,
 
1
 
 Daniëlle J.E.B. Krooshoop,
 
2
 
 Diana Dudziak,
 
3
 
 
Elisabeth Kremmer,
 
3, 4
 
 Christine Kuhnt,
 
1
 
 Carl G. Figdor,
 
2
 
Gerold Schuler,
 
1
 
 and Alexander Steinkasserer
 
1
 
1
 
Department of Dermatology, University of Erlangen-Nuremberg, D-91052 Erlangen, Germany
 
2
 
Department of Tumor Immunology, NCMLS/187 Til, University Medical Center, 6500HB 
Nijmegen, Netherlands
 
3
 
Institute of Clinical Molecular Biology and Tumor Genetik, and the 
 
4
 
Institute of Molecular 
Immunology, GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbH, D-81377
Munich, Germany
 
Abstract
 
CD83 is an immunoglobulin (Ig) superfamily member that is upregulated during the matura-
tion of dendritic cells (DCs). It has been widely used as a marker for mature DCs, but its func-
tion is still unknown. To approach its potential functional role, we have expressed the extracel-
lular Ig domain of human CD83 (hCD83ext) as a soluble protein. Using this tool we could
show that immature as well as mature DCs bind to CD83. Since CD83 binds a ligand also ex-
pressed on immature DCs, which do not express CD83, indicates that binding is not a ho-
mophilic interaction. In addition we demonstrate that hCD83ext interferes with DC matura-
tion downmodulating the expression of CD80 and CD83, while no phenotypical effects were
observed on T cells. Finally, we show that hCD83ext inhibits DC-dependent allogeneic and
peptide-specific T cell proliferation in a concentration dependent manner in vitro. This is the
first report regarding functional aspects of CD83 and the binding of CD83 to DCs.
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Introduction
 
Dendritic cells (DCs)
 
*
 
 are the most potent APCs of the im-
mune system. DC maturation, with its associated functional
and phenotypic changes is crucial to this role. In their im-
mature state, DCs reside in peripheral tissues. Upon anti-
gen uptake and inflammatory and microbial stimuli, they
start to migrate to the T cell areas of the peripheral lymph
nodes, where as mature DCs, they express additional mole-
cules that will lead to binding and stimulation of T cells,
while losing their ability for antigen-capturing (1–3). In
this respect, CD83 is the best known marker for mature
DCs. Human CD83 (hCD83) is a 45-kD glycoprotein and
member of the Ig superfamily (4, 5). Recently, also the
cloning and biochemical characterization of the murine
CD83 (mCD83) has been reported (6, 7). mCD83 shares
an amino acid identity of 63% with hCD83 suggesting a
possibly conserved function.
The selective expression and upregulation together with
costimulatory molecules like CD80 and CD86 suggests an
important role of CD83 in the immune response (4, 8–10).
Although the precise function of CD83 is still unknown
(no inhibitory antibody exists), we have recently shown
that by interfering with the translocation of mRNA encod-
ing CD83 and thus inhibiting CD83 protein synthesis, the
T cell stimulation capacity of DCs was significantly reduced
(11). In addition, we demonstrated a selective downregula-
tion of the surface expression of CD83 after the infection
of mature DCs with Herpes simplex virus type 1 and a re-
duced ability to stimulate allogeneic T cells in mixed leu-
kocyte reactions (MLRs; reference 12). These observations
indicated, but did not prove a critical role for CD83.
Here we report the recombinant expression and pu-
rification of the extracellular domain of the hCD83
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(hCD83ext). Interestingly, hCD83ext completely abro-
gates the DC-mediated primary allostimulation of T cells in
vitro. Furthermore, also the capacity to stimulate antigen
specific T cells was inhibited by this soluble molecule. This
is the first report describing a functional role for CD83
which will contribute to a better understanding of the DC
biology in general and will hopefully lead to the develop-
ment of new therapeutic strategies. Finally, we show that
CD83 binds to immature as well as mature DCs.
 
Materials and Methods
 
Cloning of hCD83ext.
 
The extracellular domain of human
CD83 (amino acids 23–128) was PCR-amplified using the fol-
lowing primers: sense- pGEX2ThCD83: 5
 
 
 
-TCCCCCGG-
GAACGCCGGAGGTGAAGGTGGCT-3
 
 
 
 and antisense-CD83
extra: 5
 
 
 
-AATTAGAATTCTCAAATCTCCGCTCTGTATT-3
 
 
 
.
The amplified fragment was subcloned into the 
 
SmaI
 
 and 
 
EcoRI
 
sites of the expression vector pGEX2T (Amersham Pharmacia
Biotech) resulting in the plasmid pGEX2ThCD83ext and trans-
formed into the 
 
E.coli
 
 strain TOP10F` (Invitrogen). The correct
insert was verified by sequencing.
 
Expression and Purification of hCD83ext.
 
The expression of
hCD83ext was induced in 
 
Escherichia coli
 
 as described previously
(7). Briefly, the cells were then pelleted and resuspended in 10 ml
native buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na
 
2
 
HPO
 
4
 
,
1.8 mM KH
 
2
 
 PO
 
4
 
, 2.6 mM MnCl, 26 mM MgCl
 
2
 
, 1 
 
 
 
g/ml leu-
peptin, 1 
 
 
 
g/ml aprotinin, 1 
 
 
 
g/ml DNaseI, pH 7.6) per 500 ml
culture. 50 
 
 
 
g/ml lysozyme were also added. After 15-min incu-
bation on ice the lysate was spun at 20,000 
 
g
 
. Protein purification:
capture step: 40 ml supernatant were added to a GSTrap 5 ml
column on an ÄKTA Explorer 10 system (Amersham Pharmacia
Biotech). Binding buffer: PBS (140 mM NaCl, 2.7 mM KCl, 10
mM Na
 
2
 
HPO
 
4
 
, 1.8 mM KH
 
2
 
 PO
 
4
 
, pH 7.6). Elution buffer: 50
mM Tris-HCl, pH 8.0, with 5 mM reduced glutathione. Flow
rate: 5 ml/min. Chromatographic procedure: 4CV (column vol-
umes) binding buffer, 40 ml supernatant, 12CV binding buffer,
5CV elution buffer, 5CV 2N NaCl/PBS, pH 7.6, 5CV binding
buffer. Intermediate purification steps: The GST-hCD83ext con-
taining elutions were dialysed against 50 mM 1-methyl-pipera-
zine, 50 mM Bis-Tris, 25 mM Tris, pH 9.5 (buffer A), and
loaded onto source 15Q PE 4.6/100 anion exchange column on
a ÄKTA Explorer 10 system. Proteins were separated by three
different linear salt gradients: 16CV to target concentration 10%
buffer B (buffer A/1N NaCl). 20CV to target concentration 50%
buffer B. 10CV to target concentration 100% buffer B. The
GST-hCD83ext containing elutions were dialysed against PBS,
pH 7.6. Then the GST-hCD83ext. fusion protein was incubated
with Thrombin 20 U/ml at 22
 
 
 
C for 16 h. To separate the
hCD83ext protein from GST the elution was loaded onto pre-
packed glutathione sepharose 4B columns using the capture step
buffer conditions. Under binding buffer conditions the flow
through containing recombinant human CD83ext protein was
collected. Polishing step: finally a preparative gel filtration separa-
tion was performed loading the flow through onto a Superdex 75
(26/16) prep grade column on a ÄKTA Explorer 10 system, run-
ning buffer PBS, pH 7.6, flow rate 3 ml/min. The GST protein
was used as a negative control in functional analyses.
 
Expression and Purification of Recombinant CD83-Fc-Fusion Pro-
tein.
 
CD83-Fc was constructed by fusing the extracellular do-
main of CD83 with the Fc part of human IgG1. A PCR product
of the extracellular domain of CD83 was amplified using Pfu
 
polymerase (Promega). The CD83 sense primer contains a 
 
XhoI
 
restriction site (5
 
 
 
-GCGGGGCTCGAGGCCACCATGTCG-
CGCGGCCTCCAGCTTCTGC) and the antisense primer a
 
BglII
 
 restriction site (5
 
 
 
-CCCCGGAGATCTGCAGGGCATC-
CTGTCACTCTCA). PCR conditions were as follows: 2 min
94
 
 
 
C; 35
 
 
 
 (1 min 94
 
 
 
C, 1 min 56
 
 
 
C, 1 min 72
 
 
 
C); 10 min 72
 
 
 
C.
The PCR product was purified using a PCR purification kit
(QIAGEN). After digestion with 
 
XhoI
 
 and 
 
BglII
 
 the PCR prod-
uct was cloned into the 
 
XhoI
 
 and 
 
BamHI
 
 sites of the pCDM7
vector (a gift from Kolanus, Genecenter, Munich, Germany)
containing the Fc part of IgG1 and transformed into MC1061P3
bacteria. The construct was sequenced in order to exclude possi-
ble mutations (Sequiserve). 293-T cells, cultured in DMEM me-
dium (Life Technologies) supplemented with 2 mM 
 
L
 
-glutamine
(Life Technologies), 100 U/ml penicillin/streptomycin (Life
Technologies), 1 mM sodium-pyruvat (Life Technologies), and
10% FBS (Dynacyte), were transiently transfected with CDM7/
CD83-Fc using LipofectAMINE™ reagent and OPTIMEM 1
medium (Life Technologies). 293-T cells were cultured 10 d in
serum free medium (293 SFMII; Life Technologies). Secretion of
recombinant CD83-Fc protein into the supernatant was verified
by Western blot analysis. The CD83-Fc fusion protein was puri-
fied by protein A-Sepharose affinity chromatography (Amersham
Pharmacia Biotech).
 
Production of mAbs Against Human CD83.
 
 
 
50 
 
 
 
g of the
hCD83ext-GST fusion protein were injected intraperitoneally
and subcutaneously into LOU/C rats. After a 2-mo interval a fi-
nal boost with the antigen was given intraperitoneally and subcu-
taneously 3 d before fusion. Fusion of the myeloma cell line
P3X63-Ag8.653 with the rat immune spleen cells was performed
according to standard procedure. Hybridoma supernatants were
tested in a solid-phase immuno assay using the hCD83ext-GST
protein adsorbed to polystirene microtiter plates. After incubation
with culture supernatants for 1 h, bound mAbs were detected
with peroxidase-labeled goat anti–rat IgG
 
 
 
plus IgM antibodies
(Dianova) and 
 
O
 
-phenylenediamine as chromogen in the peroxi-
dase reaction. An irrelevant GST-fusion protein served as a nega-
tive control. Ig type of the monoclonal antibodies was deter-
mined using biotinylated anti–rat IgG subclass-specific mAbs
(American Type Culture Collection). CD83–1G11 (rat IgG1)
and CD83–4B5 (rat IgG2a) were used for Western blot analysis
and FACS
 
®
 
 analysis. Both detected specifically human CD83.
Functional studies revealed, that, like the commercially available
anti-CD83 antibodies, these antibodies had no inhibitory activity.
 
Immunoblotting Analyses.
 
Western blot analyses of purified
protein was performed as described previously (12) using mono-
clonal anti-CD83 antibodies (CD83–1G11; CD83–4B5 both de-
scribed in this paper; and anti-CD83 from Immunotech).
 
1-D NMR Studies.
 
1-D NMR studies were recorded with a
sample of the hCD83ext using a Bruker AM 400 spectrometer at
a temperature of 300K as described previously (7).
 
Generation of DCs.
 
DCs were generated from PBMCs in the
presence of GM-CSF and IL-4 as described previously (12). For
the final DC maturation the medium containing 1% human
plasma, GM-CSF and IL-4 was supplemented with IL-1
 
 
 
 (1 ng/
ml), TNF-
 
 
 
 (1.25 ng/ml), and prostaglandin E
 
2
 
 (0.5 
 
 
 
g/ml)
(maturation mix).
 
Plate Adhesion Assay.
 
A 96-well flat-bottomed plat (Maxi
Sorp; Nunc) was precoated with 50 
 
 
 
l goat anti–human Fc-spe-
cific F(ab
 
 
 
)
 
2
 
 (4 
 
 
 
g/ml, Jackson ImmunoResearch Laboratories) or
with 50 
 
 
 
l rat anti–human GST (1 mg/ml) for 1 h at 37
 
 
 
C and
blocked with 1% BSA in Tris-sodium buffer (20 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 1 mM CaCl
 
2
 
, 2 mM MgCl
 
2
 
) for 30 min 
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at 37
 
 
 
C. Subsequently, the plate was incubated with 500 ng/ml
intercellular adhesion molecule (ICAM)-I-Fc (13), 500 ng/ml
CD83-Fc or 500 ng/ml GST. 40,000 cells per well were labeled
in PBS with Calcein-AM (25 
 
 
 
g/10
 
7
 
 cells per milliliter; Molecu-
lar Probes) for 30 min at 37
 
 
 
C. Labeled cells were washed and
preincubated for 10 min with different concentrations of recom-
binant hCD83ext or medium at RT. Cells were allowed to ad-
here for 45 min at 37
 
 
 
C. Adherent cells were lysed with 100 
 
 
 
l
lysis buffer (50 mM Tris, 0.1% SDS), and the fluorescence was
quantified using a Cytofluor II (Perseptive Biosystems) or a Vic-
tor (Wallac) fluorometer. Results are expressed as the mean per-
centage of cells binding from triplicate wells.
 
Coating of Beads with CD83-Fc.
 
Streptavidin-coated Trans-
FluorSpheres (488/645 nm; 1.8 
 
 
 
m; Molecular Probes) were
generated as described previously (13). The streptavidin-coated
beads (15 
 
 
 
l) were incubated with biotinylated goat anti–human
anti-Fc F(ab
 
 
 
)
 
2
 
 fragments (33 
 
 
 
g/ml) in 0.3 ml PBS, 0.5% BSA
for 2 h at 37
 
 
 
C. The beads were washed once with PBS, 0.5%
BSA, and incubated with CD83-Fc (500 ng/ml) in 500 
 
 
 
l PBS,
0.5% BSA overnight at 4
 
 
 
C. The binding efficiency was deter-
mined by FACS
 
®
 
 analysis.
 
FACS
 
®
 
 Analysis.
 
Phenotypic analysis of cells or beads were
performed by flow cytometry using saturating concentrations of
the following mAbs: CD83 (CD83–1G11; CD83–4B5 both de-
scribed in this paper and anti-CD83 from Immunotech); CD80
(Immunotech); CD14 and CD86, MHC-I (Dianova); CD3 (Bio
Research), CD4, CD8, CD45RO, and CD45RA (Dako). The
isotype controls IgG1a, IgG2a, and IgG2b (Becton Dickinson)
were run in parallel. Cells were analyzed on a FACScan™ (Bec-
ton Dickinson). Nonviable cells were gated out on the basis of
their light scatter properties.
 
Allogeneic T Cell Proliferation.
 
Human PBMCs were isolated
from buffy coats and the T cell fraction was purified by rosetting
with neuramidase-treated sheep RBCs as described by Bender et
al. (14). The CD4- and CD8-positive T cells were stimulated at
different ratios with mature allogeneic DCs. DCs were treated
with different concentrations of hCD83ext. GST or BSA was
 
used as negative control (Bio-Rad Laboratories). CD83-Fc
coated beads were also used for inhibitory studies. In these exper-
iments uncoated beads were used as negative control. T cell pro-
liferation was determined as described previously (12).
 
Enzyme-linked Immunospot Assay.
 
Assessment of the IFN-
 
 
 
production by the influenza matrix peptide M1 specific CTL
clone (C9) was performed as described previously (15). The
HLA-A2.1 restricted M1 peptide (GILGFVFTL, amino acids 58–
66) was used at a concentration of 10 
 
 
 
M. The number of spots
forming cells were counted with a video imaging analysis system
(Carl Zeiss Vision), using the KS enzyme-linked immunospot as-
say (ELISPOT) software version 4.1.143.
 
Results
 
Recombinant Protein Expression.
 
The extracellular do-
main of hCD83 (hCD83ext) was expressed in 
 
E.coli
 
 as a
gluthatione S-transferase (GST) fusion protein in sufficient
quantities. For functional studies the fusion protein was
cleaved by thrombin and only the hCD83ext was used,
whereas GST served as a negative control. The correct ex-
pression of the protein was analyzed by silver staining and
Western blot analysis (Fig. 1 A and B). Amino-terminal
amino acid sequencing analyses further confirmed the cor-
rect identity of the purified protein (data not shown). To
determine whether or not the recombinant protein was
correctly folded, one-dimensional NMR studies were
performed. The 1-D NMR spectrum of hCD83ext at
300K showed chemical dispersion typical of a structured
protein (Fig. 1 C). The presence of slowly exchanging
amide resonances (
 
 
 
7–9 ppm) indicates that certain parts
of the protein backbone are protected from solvent.
Downfield-shifted 
 
 
 
-CH resonances (
 
 
 
4.5–5.7 ppm) are
indicative of 
 
 
 
-structures. Upfield-shifted methyl reso-
nances (
 
    
 
0.9 ppm) provide further evidence of the
Figure 1. Biophysical analyses of recombinant hCD83ext. (A) hCD83ext was separated by SDS-PAGE and silver
stained. (B) Western blot analysis of the blotted hCD83ext using monoclonal anti-CD83 antibodies and (C) one-dimen-
sional NMR spectrum, showing that hCD83ext is folded. 
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protein being folded. These NMR data strongly support
that the recombinant expressed hCD83ext. is structurally
folded and relevant functional studies can be performed
using this protein.
 
Human CD83 Binds to Immature and Mature DCs.
 
To
establish the cell surface binding of human CD83 a stan-
dard plate adhesion assay was employed. As shown in Fig.
2 immature day 4 DCs as well as mature day 7–8 DCs
(Fig. 2 A and B, respectively) bind to human CD83. This
binding could be inhibited in a concentration-dependent
manner by the recombinant expressed extracellular do-
main of CD83 (hCD83ext). Binding to ICAM-1-Fc as a
control could not be inhibited by hCD83ext. Uncoupled
GST served as a negative control. The binding of ICAM-1
and beads was not specifically influenced by hCD83ext.
In addition, as shown in Fig. 2 C, binding of DCs to
CD83 is concentration dependent. The specific binding
was lost when decreasing amounts of CD83-Fc were used
(Fig. 2 C).
Interestingly, we could not demonstrate binding of na-
ive CD4
 
 
 
or CD8
 
 
 
 T cells to CD83 (data not shown).
From these data we conclude that immature and mature
DCs bind specifically to CD83 and that the recombinant
prokaryotic expressed hCD83ext could be used for further
functional studies, indicating that glycosylation is not nec-
essary. Furthermore, the fact that immature DCs, which
do not express CD83, also bind to CD83 implies that
there is no homophilic interaction between CD83 mole-
cules. Therefore, it is most likely a heterophilic binding
reaction.
 
hCD83ext Induces Downmodulation of Specific Molecules on
DCs.
 
To analyze the influence of hCD83ext on the phe-
notype of DCs, FACS
 
®
 
 analyses were performed on day 8
(Fig. 3). DCs can be fully matured with the use of a specific
maturation cocktail composed of IL-1
 
 
 
, TNF-
 
 
 
, and
PGE2. Interestingly, when this maturation cocktail was ad-
ministered to immature DCs on day 5 together with
hCD83ext (4  g/ml) and left until the final FACS® analy-
ses on day 8, these cells revealed a clear reduction in CD80
(from 96 to 66%) and CD83 cell surface expression (96–
30%), when compared with normally matured DCs (com-
pare Fig. 3 A with C). Thus, hCD83ext induces a reduc-
tion in DC maturation (see also increase of CD14-positive
cells). In contrast, mature DCs which where incubated
with hCD83 for 24 h on day 7 and analyzed on day 8,
showed only a minimal influence on CD80 expression
(96–92%), while CD83 expression was also reduced (96–
66%) (compare Fig. 3 A with B). Interestingly, CD86 ex-
pression was not influenced at any time point by the
administration of hCD83ext. Also MHC class I and II ex-
pression was not affected, neither in immature nor in ma-
ture DCs. Noteworthy, no significant phenotypical changes
Figure 2. Plate adhesion assay. ICAM-Fc and hCD83-Fc were bound
to goat anti–human Fc-specific F(ab )2 precoated plates. Calcein-AM la-
beled DCs (40,000) were allowed to adhere for 45 min at 37 C. Fluores-
cence of adherent cells was quantified using fluorometric analyses. Clearly,
immature (A) as well as mature (B) DCs bind to CD83. Preincubation of
labeled DCs with recombinant hCD83ext inhibited the binding of the im-
mature and mature DCs to plate-bound CD83-Fc. The binding could
be inhibited in a concentration-dependent manner (5 and 20  g/ml
hCD83ext). Binding to ICAM-1-Fc as a control could not be inhibited by
hCD83ext, while GST was used as a negative control. Both were not spe-
cifically influenced by the addition of hCD83ext. In addition the binding
of DCs to CD83 was concentration dependent (C). The binding was lost
when decreasing amounts of CD83-Fc were used. In these experiments,
Ig coated via goat anti–human-Fc, was used as negative control. The Ig
binding was not influenced by hCD83ext. These experiments were per-
formed five times using different donors for DC generation. This repre-
sents a typical experiment.1817 Lechmann et al.
could be observed within T cell populations by the addi-
tion of hCD83ext (data not shown), indicating that CD83
affects primarily DCs.
hCD83ext Inhibits Allogeneic T Cell Proliferation. MLRs
are a simple, yet very powerful tool in order to analyze the
T cell stimulatory capacity of DCs. A typical feature of
these MLR-assays is the formation of large DC–T cell clus-
ters. Addition of hCD83ext at day 1 strongly inhibited the
typical cell cluster formation of DCs and proliferating T
cells, whereas GST had no influence (data not shown). As
shown in Fig. 4 A hCD83ext strongly inhibited [3H]thymi-
dine incorporation in a dose–dependent manner. GST,
which was expressed and purified in the same way as
hCD83ext, was used as negative control and had, like BSA,
no influence on T cell proliferation. Also the CD83-Fc
molecule (expressed in an eukaryotic system) coupled to
beads inhibited T cell proliferation (Fig. 4 B). These find-
ings indicate again that CD83-glycosylation is not a prereq-
Figure 3. FACS® analyses of DCs. (A) Immature DCs
were matured in the presence of the maturation cocktail
from day 5–8 (  mock control for mature DCs). (B) Imma-
ture DCs where matured in the presence of the maturation
cocktail (day 5–8) and on day 7 hCD83ext was added for
24 h. (C) Immature DCs where incubated in the presence
of the maturation cocktail in combination with hCD83
from day 5–8. On day 8 cells where washed and stained
with the indicated antibodies and analyzed by FACS®.
Figure 4. hCD83ext inhibits allogeneic T cell proliferation. (A) MLR
analyses: the prokaryotic expressed hCD83ext reduced T cell prolifera-
tion in a dose-dependent manner. GST, which was purified in the same
way as hCD83ext and BSA (each 5  g/ml) were used as controls. (B)
Also the eukaryotic expressed CD83–Fc fusion protein couplet to beads
inhibits T cell proliferation. Uncoupled beads alone were used as a nega-
tive control and hCD83ext as a positive control. (C) The inhibition is not
due to a contamination: to prove that the purified hCD83ext protein was
responsible for the inhibitory activity and not a possible contamination
present in the protein preparation, purified hCD83ext was filtered using a
10-kD Microcon system. Filtered and unfiltered hCD83ext exhibit com-
parable inhibitory effects. Whereas, cells which were treated with the fil-
trate alone showed no inhibition and the stimulation was comparable to
mock-treated cells. All experiments were performed at least three times.
Data presented here represent a typical experiment.1818 Soluble CD83
uisite, since the prokaryotic expressed hCD83ext also in-
hibits T cell proliferation.
To prove that the inhibitory effects of hCD83ext are
not due to cytotoxic effects, day 5 DCs were incubated
for 24 h with 5  g/ml hCD83ext together with the final
maturation mix. Then, hCD83ext was washed out, new
maturation mix was added and the allostimulatory capac-
ity of these cells was determined. Interestingly, T cell pro-
liferation was not inhibited when hCD83ext has been
washed out (data not shown). These data clearly show
that hCD83ext is not cytotoxic and indicate that
CD83ext must be present during the experiment to ex-
hibit its inhibitory function.
To further demonstrate that the purified protein itself
was responsible for the inhibitory activity and not a possi-
ble contamination present in the protein preparation, puri-
fied hCD83ext was filtered using a 10-kD Microcon sys-
tem. Then, the filtered protein as well as the filtrate were
tested (Fig. 4 C). These experiments clearly show that the
filtered hCD83ext protein was responsible for the inhibi-
tory effects, while the filtrate had no influence on the T
cell proliferation.
To demonstrate that hCD83ext had no toxic effects on
T cell level, cell viability was determined using the trypan
blue exclusion method. T cells were incubated with
hCD83ext (4  g/ml) for 4 d and compared with control
cells (incubated with 4  g/ml BSA). No significant de-
crease in T cell viability, after incubation with inhibitory
concentrations of hCD83ext were detected (data not
shown). Therefore, T cell death seems not responsible for
the reduced proliferation.
hCD83 Inhibits Proliferation of Influenza Virus Specific
CTLs. The ELISPOT assay is a very useful tool to ana-
lyze DC-mediated proliferation of specific CTLs, assessing
the cytokine release at a single cell level. Furthermore, it
can also be used for direct ex vivo quantification of pep-
tide-reactive T cell responses. In this study we used the in-
fluenza matrix peptide M1 specific CTL clone C9 (16).
HLA-A2.1 positive DCs were incubated with the M1-pep-
tide and then cocultivated with different numbers of CTLs.
A computer-assisted video image analysis system was used
for the evaluation of the experiments (17). Again, increas-
ing amounts of hCD83ext resulted in a clear reduction of
CTL specific responses (Fig. 5), indicating that the interac-
tion between DCs and peptide specific T cells is inhibited.
Secondary Stimulation of hCD83ext Treated T Cells. To
investigate whether or not the proliferation arrest of
hCD83ext treated T cells can be overcome, cells from the
primary MLRs, which have been either incubated with or
without hCD83ext, were stimulated for a second time pe-
riod of 4 d without the addition of hCD83ext. For this,
half of the medium was discharged and new medium con-
taining IL-2 at a final concentration of 500 U/ml or with-
out IL-2 was added to the cultures. After an incubation of
3 d, cells were pulsed and T cell proliferation was deter-
mined (Fig. 6 A). Interestingly, T cells which were
strongly inhibited by hCD83ext in the primary MLRs
could be restimulated with IL-2. The proliferation was
comparable to that obtained by untreated cells in the pri-
mary MLRs. These data clearly show that the proliferation
arrest in T cells, caused by hCD83ext, is not due to an ir-
reversible toxic effect. In fact proliferation can be restored
using IL-2. Furthermore, to investigate this phenomenon
in a more physiological setting, T cells which were inhib-
ited with hCD83ext in the primary MLRs, were restimu-
lated with allogeneic DCs, instead of IL-2 (Fig. 6 B).
Again, arrested T cells could be restimulated with DCs,
reaching stimulation levels comparable to those obtained
with untreated cells in primary MLRs. Thus the inhibitory
effect of hCD83ext is reversible and is not mediated via T
cell anergy.
Discussion
DCs act as nature’s adjuvant in inducing T cell–medi-
ated immunity. To understand the biological properties of
DCs it is vital to gain further knowledge regarding the role
of DCs specific proteins on a molecular level. Here, we
provide for the first time evidence that CD83, the best
known cell surface marker for mature DCs, has also a bio-
logical function. During DC maturation CD83 is rapidly
upregulated together with the costimulatory molecules
CD80 and CD86. These molecules provide the so-called
second signal for the T cell activation (18). Multiple studies
have shown that allostimulation can be prevented by
blocking the CD28-mediated costimulatory signals using
either anti–CD80/CD86 mAbs or the fusion protein
CTLA4Ig (19–23). As a result this blockage of signal two
leads to T cell anergy.
Although CD83 is strongly upregulated on mature DCs
the function of this molecule has been unknown to date.
Figure 5. hCD83ext inhibits proliferation of influenza matrix peptide
M1-specific CTL clone. DCs were loaded with influenza matrix peptide
M1 and used to assess the stimulation (IFN-  production) of the M1-spe-
cific CTL clone C9. Number of IFN- –producing spot are shown on the
y-axis. Increasing concentrations of hCD83ext clearly reduced the num-
ber of spot forming cells. GST, which was purified in the same way as
hCD83ext was used a negative control. Three independent experiment
were performed. The data presented represent a typical experiment.1819 Lechmann et al.
To elucidate the mode of action of CD83 the extracellular
Ig domain of human CD83 was expressed as a recombinant
protein and used for functional studies in vitro. 1D-NMR
data strongly support that the recombinant hCD83ext is
correctly folded and therefore the suppressive effects ob-
served in the T cell assays are due to a functionally active
molecule. In addition, a CD83-Fc molecule, expressed in
an eukaryotic system was used.
Using plate adhesion analyses we could show for the first
time that immature and mature DCs bind to CD83. The
specificity of the CD83-binding to DCs could be demon-
strated by the fact that the soluble extracellular hCD83ext
domain inhibited the binding in a concentration-dependent
manner (Fig. 2 A–C). Furthermore, the binding of DCs to
CD83 itself is also concentration dependent. The binding
was lost when decreasing amounts of CD83 were used (Fig.
2 C). These findings are highly relevant for several aspects:
(i) since hCD83ext, which was expressed in a prokaryotic
system, inhibits the binding of the eukaryotic expressed
CD83-Fc underlines the fact that glycosilation is not neces-
sary for CD83 binding to its ligand; (ii) the prokaryotic ex-
pressed hCD83ext protein is functionally active; (iii) the
fact that CD83 binds also to immature DCs, which do not
express CD83, indicates that there is no homophilic inter-
action between CD83 molecules. These findings rather
suggest the existence of a heterophilic binding.
Interestingly, immature DCs which were incubated with
soluble hCD83ext could not be fully matured anymore.
Even in the presence of the potent maturation cocktail
composed of IL-1 , TNF- , and PGE2 the maturation was
blocked. hCD83ext treatment lead to the specific down-
modulation of CD80, a crucial costimulatory molecule and
of CD83 itself. This suggests, that soluble hCD83ext in-
duces a maturation block, which could be a regulatory
mechanism in order to control immune responses. In this
respect it is very interesting to know that a soluble form of
CD83, like described for CD86 (24), has been character-
ized in vivo and is detectable in normal human sera and is
released from activated DCs and B cells (25), underlying a
possible important role in the regulation of immune re-
sponses. In addition, also mature DCs downmodulate
CD83 from their cell surface when incubated with
hCD83ext, indicating a regulatory mechanism also on ma-
ture DCs. The soluble molecule may either work by deliv-
ering a negative signal or blocking a positive signal that
might be generated by interactions of maturing DCs.
However, this hypothesis has to be proven in an experi-
mental setting.
Furthermore, when mature DCs were incubated with
soluble hCD83ext they completely lost their ability to
stimulate allogeneic T cell responses. In addition, also CTL
specific T cell responses were inhibited by hCD83ext.
Again, the existence of a soluble form of CD83 in vivo (25)
is an additional support of our data regarding the inhibitory
effects of hCD83ext.
Noteworthy, these effects are not due to cytotoxic ef-
fects on T cells. We demonstrate that T cells can be restim-
ulated either with IL-2 or with allogeneic DCs. This repre-
sents a novel mechanism which is not connected to T cell
anergy, induced by the inhibition of the B7-CD28 costim-
ulatory pathway (23). Since the inhibition mediated by
hCD83ext is a competitive inhibition, hCD83ext has to
be present throughout the experiment. Dilution of the
hCD83ext concentration with medium alone allowed al-
ready the restimulation of T cells. Also the number of
APCs is crucial. High numbers of DCs can only be blocked
with correspondingly higher hCD83ext concentrations.
Considering recent results, it becomes clear that CD83
plays an important role in DC biology. Previously, we
could show that inhibition of CD83 expression, by inter-
fering with a specific RNA export pathway, leads to a clear
Figure 6. Proliferation arrest of hCD83ext-treated T cells can be re-
stored. (A) hCD83ext-treated T cells derived from the primary MLRs,
which have been either treated with or without hCD83ext, were stimu-
lated for a second time period of 4 d without the addition of hCD83ext.
Medium containing IL-2 or medium without IL-2 was added to the cul-
tures. After a 3-d incubation period proliferation was determined. T cells
which were strongly inhibited by hCD83ext in the primary MLRs could
be restimulated with IL-2, clearly showing that the proliferation arrest,
caused by hCD83ext in the primary MLRs, is not due to an irreversible
toxic effect. (B) T cells which were inhibited with hCD83ext (4  g/ml)
in the primary MLRs (ratio DC:T cell   1:20), were restimulated with
allogeneic DCs (ratio 1:20). Arrested T cells could be restimulated with
DCs, reaching stimulation levels comparable to those obtained with un-
treated cells in primary MLRs. Thus, the inhibitory function of
hCD83ext is reversible. Experiments were performed at least three times.
The data presented here represent a typical experiment.1820 Soluble CD83
reduction of DC-mediated T cell stimulation (11). An ad-
ditional indication, pointing toward the biological impor-
tance of CD83 is the fact that several viruses including her-
pes simplex virus type 1 and pox viruses downregulate
CD83 (12, 26). Interestingly, these virus infected DCs are
also inhibited in their allostimulatory capacity (12, 26–29).
Nevertheless, regarding the biological function of CD83,
these reports provided only circumstantial evidence.
In contrast, here we report the identification of CD83
binding to DCs and the characterization of a reversible in-
hibitor of DC-mediated T cell stimulation, representing a
new tool to explore DC biology and new therapeutic strat-
egies. Future studies including the use of k.o. mice will
help to elucidate the biological role of CD83 even in more
detail. Further characterizations are also needed regarding
the CD83 structure and the characterization of the ligand(s)
present on DCs.
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